Unadjuvanted intranasal spike vaccine booster elicits robust protective mucosal immunity against sarbecoviruses
Mao, T.; Goldman-Israelow, B.; Suberi, A.; Zhou, L.; reschke, m.; pena-hernandez, M.; Dong, H.; Homer, R.; Saltzman, M.; Iwasaki, A.
Show abstract
As the SARS-CoV-2 pandemic enters its third year, vaccines that not only prevent disease, but also prevent transmission are needed to help reduce global disease burden. Currently approved parenteral vaccines induce robust systemic immunity, but poor immunity at the respiratory mucosa. Here we describe the development of a novel vaccine strategy, Prime and Spike, based on unadjuvanted intranasal spike boosting that leverages existing immunity generated by primary vaccination to elicit mucosal immune memory within the respiratory tract. We show that Prime and Spike induces robust T resident memory cells, B resident memory cells and IgA at the respiratory mucosa, boosts systemic immunity, and completely protects mice with partial immunity from lethal SARS-CoV-2 infection. Using divergent spike proteins, Prime and Spike enables induction of cross-reactive immunity against sarbecoviruses without invoking original antigenic sin. One-sentence summaryBroad sarbecovirus protective mucosal immunity is generated by unadjuvanted intranasal spike boost in preclinical model.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Ending transmission of SARS-CoV-2: sterilizing immunity using an intranasal subunit vaccine 97%
- Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine 97%
- A novel Mycobacterium tuberculosis-specific subunit vaccine provides synergistic immunity upon co-administration with Bacillus Calmette-Guerin 97%
Similar papers in this journal
- Mucosal immunity against SARS-CoV-2 variants of concern including Omicron following vaccination 96%
- Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2 96%
- Longitudinal Analysis Reveals Distinct Antibody and Memory B Cell Responses in SARS-CoV2 Naïve and Recovered Individuals Following mRNA Vaccination 95%
Similar papers in this journal
- Robust immune responses after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals 97%
- Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains 97%
- Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers 96%
Similar papers in this journal
- Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques 97%
- Memory B cell Development in Response to mRNA SARS-CoV-2 and Nanoparticle Immunization in Mice 96%
- Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages 96%
Similar papers in this journal
- Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory 97%
- Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination 96%
- Broadly neutralizing antibodies target the coronavirus fusion peptide 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.